C8β Inhibitors
The class of C8β inhibitors comprises a diverse set of compounds that either directly or indirectly modulate the activity of the C8β protein, which is involved in intracellular calcium signaling. One such inhibitor, RU360, specifically targets the mitochondrial calcium uniporter (MCU), preventing excessive calcium uptake into the mitochondria. This indirect inhibition influences C8β by impacting calcium-dependent signaling pathways, providing a precise means to modulate cellular processes related to C8β function. Nifedipine, a dihydropyridine calcium channel blocker, indirectly affects C8β by inhibiting L-type calcium channels. The blockade of calcium influx with Nifedipine can modulate cellular processes related to calcium-dependent pathways, impacting C8β function. KN-62, a specific CaMKII inhibitor, indirectly modulates C8β by targeting the calcium/calmodulin-dependent protein kinase II (CaMKII) pathway. As C8β is involved in calcium-dependent signaling, the inhibition of CaMKII by KN-62 influences cellular processes related to calcium signaling, impacting C8β function.
FK506 (Tacrolimus) indirectly influences C8β by inhibiting calcineurin. The disruption of calcium-dependent signaling pathways by FK506 affects C8β function, providing an indirect approach to modulate cellular processes associated with C8β. Ruthenium Red, a non-specific inhibitor of mitochondrial calcium uptake, indirectly influences C8β by blocking mitochondrial calcium transport. This inhibition can modulate cellular processes related to calcium-dependent pathways and impact C8β function. Xestospongin C, an inositol trisphosphate receptor (IP3R) antagonist, indirectly modulates C8β by inhibiting IP3R. The inhibition of IP3R can impact cellular processes related to calcium signaling, influencing C8β function. SKF-96365, a non-specific inhibitor of receptor-mediated calcium entry (RMCE), indirectly influences C8β by blocking RMCE. This inhibition can modulate cellular processes related to calcium-dependent pathways and impact C8β function. In summary, the diverse class of C8β inhibitors offers both direct and indirect means to modulate the protein's activity, impacting intracellular calcium signaling and associated cellular processes. The specific mechanisms of action of these inhibitors provide valuable tools for investigating the intricate regulatory networks governing calcium-dependent pathways and their potential connections to C8β.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator that indirectly influences C8β by sequestering intracellular calcium ions. This chelation disrupts calcium-dependent signaling pathways in which C8β participates, affecting its function. The modulation of calcium levels with BAPTA-AM provides an indirect approach to influence C8β and associated cellular processes. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine is a dihydropyridine calcium channel blocker. By inhibiting L-type calcium channels, Nifedipine indirectly affects C8β, which is involved in calcium signaling pathways. The blockade of calcium influx with Nifedipine can modulate cellular processes related to calcium-dependent pathways and impact C8β function. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $133.00 | 20 | |
KN-62 is a specific CaMKII inhibitor that indirectly modulates C8β by targeting the calcium/calmodulin-dependent protein kinase II (CaMKII) pathway. As C8β is involved in calcium-dependent signaling, the inhibition of CaMKII by KN-62 influences cellular processes related to calcium signaling, impacting C8β function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 is a myosin light chain kinase (MLCK) inhibitor that indirectly influences C8β by targeting the MLCK pathway. As C8β participates in calcium-dependent signaling, the inhibition of MLCK by ML-7 affects cellular processes related to calcium signaling, modulating C8β function. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $153.00 $600.00 | 27 | |
Calmidazolium is a calmodulin antagonist that indirectly modulates C8β by disrupting the calcium/calmodulin pathway. As C8β is involved in calcium-dependent signaling, the inhibition of calmodulin by Calmidazolium influences cellular processes related to calcium signaling, impacting C8β function. | ||||||
CGP 37157 | 75450-34-9 | sc-202097 sc-202097A | 5 mg 25 mg | $113.00 $454.00 | 3 | |
CGP-37157 is a specific inhibitor of the mitochondrial Na+/Ca2+ exchanger (NCLX). By targeting NCLX, CGP-37157 indirectly influences C8β, which is involved in intracellular calcium signaling. The inhibition of NCLX can modulate cellular processes related to calcium-dependent pathways, impacting C8β function. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506, also known as Tacrolimus, that indirectly influences C8β. By inhibiting calcineurin, FK506 disrupts calcium-dependent signaling pathways in which C8β participates, affecting its function. The modulation of calcineurin with FK506 provides an indirect approach to influence C8β and associated cellular processes. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $184.00 $245.00 | 13 | |
Ruthenium Red is a non-specific inhibitor of mitochondrial calcium uptake. By blocking mitochondrial calcium transport, Ruthenium Red indirectly influences C8β, which is involved in intracellular calcium signaling. This inhibition can modulate cellular processes related to calcium-dependent pathways and impact C8β function. | ||||||
Flunarizine • 2HCl | 30484-77-6 | sc-201473 sc-201473A sc-201473B | 1 g 10 g 50 g | $68.00 $400.00 $1683.00 | 1 | |
Flunarizine is a non-selective calcium channel blocker that indirectly influences C8β by inhibiting L-type calcium channels. As C8β participates in calcium-dependent signaling, the blockade of calcium influx with Flunarizine can modulate cellular processes related to calcium-dependent pathways, impacting C8β function. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $500.00 | 14 | |
Xestospongin C is an inositol trisphosphate receptor (IP3R) antagonist. By inhibiting IP3R, Xestospongin C indirectly modulates C8β, which is involved in calcium-dependent signaling pathways. The inhibition of IP3R can impact cellular processes related to calcium signaling, influencing C8β function. | ||||||